Literature DB >> 26097044

Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Frederick S Kaplan1,2,3, Joyce A Kobori4, Carmen Orellana5, Inmaculada Calvo6, Monica Rosello5, Francisco Martinez5, Berta Lopez6, Meiqi Xu1,2,3, Robert J Pignolo1,2,3, Eileen M Shore1,3,7, Jay C Groppe8.   

Abstract

Severe variants of fibrodysplasia ossificans progressiva (FOP) affect <2% of all FOP patients worldwide, but provide an unprecedented opportunity to probe the phenotype-genotype relationships that propel the pathology of this disabling disease. We evaluated two unrelated children who had severe reduction deficits of the hands and feet with absence of nails, progressive heterotopic ossification, hypoplasia of the brain stem, motor and cognitive developmental delays, facial dysmorphology, small malformed teeth, and abnormal hair development. One child had sensorineural hearing loss, microcytic anemia, and a tethered spinal cord and the other had a patent ductus arteriosus and gonadal dysgenesis with sex reversal (karyotype 46, XY female). Both children had an identical mutation in ACVR1 c.772A>G; p.Arg258Gly (R258G), not previously described in FOP. Although many, if not most, FOP mutations directly perturb the structure of the GS regulatory subdomain and presumably the adjacent αC helix, substitution with glycine at R258 may directly alter the position of the helix in the kinase domain, eliminating a key aspect of the autoinhibitory mechanism intrinsic to the wild-type ACVR1 kinase. The high fidelity phenotype-genotype relationship in these unrelated children with the most severe FOP phenotype reported to date suggests that the shared features are due to the dysregulated activity of the mutant kinase during development and postnatally, and provides vital insight into the structural biology and function of ACVR1 as well as the design of small molecule inhibitors.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ACVR1; ALK2; BMP receptor; FOP variant; bone morphogenetic protein (BMP); fibrodysplasia ossificans progressiva (FOP); heterotopic ossification

Mesh:

Substances:

Year:  2015        PMID: 26097044      PMCID: PMC4567450          DOI: 10.1002/ajmg.a.37205

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  28 in total

1.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Authors:  Andria L Culbert; Salin A Chakkalakal; Edwin G Theosmy; Tracy A Brennan; Frederick S Kaplan; Eileen M Shore
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

3.  Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.

Authors:  T R Clarke; Y Hoshiya; S E Yi; X Liu; K M Lyons; P K Donahoe
Journal:  Mol Endocrinol       Date:  2001-06

Review 4.  Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

5.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

6.  Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.

Authors:  Nina Renlund; Francis H O'Neill; LiHua Zhang; Yisrael Sidis; Jose Teixeira
Journal:  J Endocrinol       Date:  2007-10       Impact factor: 4.286

7.  Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects.

Authors:  A Morales-Piga; J Bachiller-Corral; M J Trujillo-Tiebas; A Villaverde-Hueso; M L Gamir-Gamir; V Alonso-Ferreira; M Vázquez-Díaz; M Posada de la Paz; C Ayuso-García
Journal:  Bone       Date:  2012-07-13       Impact factor: 4.398

Review 8.  ACVR1 mutations in DIPG: lessons learned from FOP.

Authors:  Kathryn R Taylor; Maria Vinci; Alex N Bullock; Chris Jones
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

9.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

Review 10.  Fibrodysplasia ossificans progressiva: clinical and genetic aspects.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Orphanet J Rare Dis       Date:  2011-12-01       Impact factor: 4.123

View more
  11 in total

1.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

2.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

3.  Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.

Authors:  Daniele De Brasi; Francesca Orlando; Valeria Gaeta; Maria De Liso; Fabio Acquaviva; Luigi Martemucci; Augusto Mastrominico; Maja Di Rocco
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

Review 4.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

Review 5.  ACVR1 Function in Health and Disease.

Authors:  José Antonio Valer; Cristina Sánchez-de-Diego; Carolina Pimenta-Lopes; Jose Luis Rosa; Francesc Ventura
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

6.  Social and Clinical Impact of COVID-19 on Patients with Fibrodysplasia Ossificans Progressiva.

Authors:  Samuel Kou; Sammi Kile; Sai Samhith Kambampati; Evelyn C Brady; Hayley Wallace; Carlos M De Sousa; Kin Cheung; Lauren Dickey; Kelly L Wentworth; Edward Hsiao
Journal:  Res Sq       Date:  2021-09-16

7.  Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.

Authors:  Senem Aykul; Lily Huang; Lili Wang; Nanditha M Das; Sandra Reisman; Yonaton Ray; Qian Zhang; Nyanza Rothman; Kalyan C Nannuru; Vishal Kamat; Susannah Brydges; Luca Troncone; Laura Johnsen; Paul B Yu; Sergio Fazio; John Lees-Shepard; Kevin Schutz; Andrew J Murphy; Aris N Economides; Vincent Idone; Sarah J Hatsell
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

Review 8.  BMP Signaling Pathway in Dentin Development and Diseases.

Authors:  Mengmeng Liu; Graham Goldman; Mary MacDougall; Shuo Chen
Journal:  Cells       Date:  2022-07-16       Impact factor: 7.666

Review 9.  Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.

Authors:  Takenobu Katagiri; Sho Tsukamoto; Mai Kuratani
Journal:  Biomedicines       Date:  2021-06-26

10.  A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.

Authors:  Serena Cappato; Rasa Traberg; Jolita Gintautiene; Federico Zara; Renata Bocciardi
Journal:  Mol Genet Genomic Med       Date:  2021-08-04       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.